Abstract: The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acids residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b) introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject.

Abstract: The invention relates to methods and assays for identifying compounds as candidates in the development of a drug for the treatment of various diseases including those associated with pathological Tau. The invention also relates to methods and assays for identifying compounds for the treatment of various diseases including those associated with pathological Tau. The invention also relates to cell lines and constructs for use in an assay of the invention. The methods and assays identify a compound as useful in the treatment of a tauopathy if said compound modulates Sil1 expression or activity.

Abstract: The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acids residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b) introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject.

Abstract: The invention relates to methods and assays for identifying compounds as candidates in the development of a drug for the treatment of various diseases including those associated with pathological Tau. The invention also relates to methods and assays for identifying compounds for the treatment of various diseases including those associated with pathological Tau. The invention also relates to cell lines and constructs for use in an assay of the invention. The methods and assays identify a compound as useful in the treatment of a tauopathy if said compound modulates Sil1 expression or activity.

Abstract: The invention relates to an assay for identifying compounds for the treatment of various diseases including those associated with excitotoxicity. The invention also relates to cell lines and constructs for use in an assay of the invention. The invention also relates to methods for determining whether a compound reduces excitotoxic signalling in a cell and whether a compound that inhibits binding of Tau to Fyn is likely to selectively reduce excitotoxic cell signalling. The invention also relates to a Tau protein adapted to form a detectable signal when the Tau protein is bound to a Fyn protein. The invention also relates to a Fyn protein adapted to form a detectable signal when the Fyn protein is bound to a Tau protein.